Swedish biotech Anocca has raised about 440 million Swedish kronor ($46 million) in new financing to accelerate development ...

Researchers found that the vaccine, named ELI-002 2P, could trigger lasting immune responses and may help prevent or delay ...

The FDA has awarded Breakthrough Therapy Designation to izalontamab brengitecan, a potential first-in-class bispecific ...

The Eredivisie continued with fine ferocity this weekend, as the second matchweek served up some fantastic clashes. On ...

Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

Anocca AB (‘Anocca’ or the ‘Company’), a leading clinical-stage T-cell immunotherapy company, has successfully raised SEK ~440 million (USD ~46 million) in financing. The additional capital will be ...

Anocca AB ( Anocca ), a clinical-stage T-cell immunotherapy company, raised SEK ~440 million (USD ~46 million) in financing. Mellby Gård led the financing with strong support from AMF, Ramsbury, and ...

The Eredivisie continued with fine ferocity this weekend, as the second matchweek served up some fantastic clashes. On ...

Approximately 100 kilometres from Ajanta Caves is the famous Ellora Cave, home to the famous monolithic Kailasa Temple.

The vaccine would train the immune system to fight cancer-causing mutations, according to new research from UCLA Health.

Let’s take a closer look at a few biotech stocks poised to benefit from this resurgence. Medicus Pharma Ltd. (NASDAQ: MDCX) is an emerging biotech and life sciences company with a global footprint ...

The firm will use the funding to support a Phase I/II umbrella trial of three TCR T-cell candidates and its preclinical pipeline.